Zynga’s Real-Money Gambling Cashes In and 4 Other Hot Stocks

  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

It’s a big payday for Bind Therapeutics, which will be receiving as much as $200 million per potential drug from Pfizer (NYSE:PFE) for allowing the company to use its nanotechnology platform in its product development. Bind’s nanoparticles, called Accurins, can transport drugs through the body and home in on diseased cells without harming healthy tissue, according to the company’s press release. ”Pfizer has a strong legacy in targeted small molecule drug discovery and development and continues to be on the cutting edge of innovation in this area,” said Rod MacKenzie, Senior Vice President and Head of PharmaTherapeutics R&D at Pfizer. ”We look forward to working with the team at BIND Therapeutics to create targeted Accurins with the aim of optimizing the therapeutic potential of future small molecules.”

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!


More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business